BioMimetic gets FDA panel nod by slim margin

An FDA advisory committee Thursday endorsed BioMimetic Therapeutics' ($BMTI) experimental drug-device combination product Augment, which is intended as an alternative to autograft procedures for patients who undergo certain foot and ankle repair surgeries, Dow Jones reported. The panel voted 10-8 that the Franklin, TN-based company's product provides greater benefits than risks, 12-6 in support of the safety of the treatment and 10-8 on the question of effectiveness, according to the news service. The FDA will weigh the committee's votes in deciding whether to approve the treatment. Yet the relatively slim margin of victory for BioMimetic doesn't clear up whether the agency will ultimately support the firm's application for approval. BioMimetic release | Report

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.